Dr. Dent Discusses the LOTUS Trial in Triple-Negative Breast Cancer
Rebecca Dent, MD, senior consultant, National Cancer Center, Singapore, discusses the results of the LOTUS trial in patients with triple-negative breast cancer.
Rebecca Dent, MD, senior consultant, National Cancer Center, Singapore, discusses the results of the LOTUS trial in patients with triple-negative breast cancer (TNBC).
The primary endpoint of the study was progression-free survival (PFS). There was modest improvement in the overall intent-to-treat population. However, researchers saw a big impact on PFS in the biomarker-positive group.
A panel was done by Foundation Medicine on either archived or fresh tissue that looked at PIK3CA, AKT, or PTEN. Patients with those alterations showed a 4- to 5-month improvement in PFS which Dent states is a fairly profound improvement in PFS in TNBC.
Researchers also looked at response, duration of response (DOR), and clinical benefit rate. The same trend was seen in terms of improved outcomes with ipatasertib, but the real benefit, says Dent, was seen in the DOR. The DOR almost doubled with the addition of ipatasertib in the biomarker-positive population. The phase III study is ongoing.
